Credit: Towfiqu Barbhuiya/Adobe Stock
The Federal Trade Commission and the pharmacy benefit managers it's accusing of artificially inflating insulin prices are hitting a host of prominent companies, from McDonald's to the HR consultancy Mercer, with massive document requests in search of information to buttress their positions.
Since the FTC brought its case in September, at least 10 nonparty companies—from insulin makers to past and current clients of the PBMs—have received subpoenas. McDonald's said in a Jan. 31 filing that it had fully complied with the FTC's subpoena after reviewing thousands of documents and submitting more than 1,300 but was still working on producing documents for PBMs.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
